# INVESTOR PRESENTATION

### JUNE 2021

### DISCLAIMER

This Presentation contains certain forward-looking statements. These statements may be made directly in this Presentation. Some of the forward-looking statements can be identified by the use of forward-looking words. Statements that are not historical in nature, including the words "anticipate," "expect," "suggests," "plan," "believe," "intend," "estimates," "targets," "projects," "should," "could," "would," "may," "will," "forecast" and other similar expressions are intended to identify forward-looking statements. All forward-looking statements are based upon management estimates and forecasts and reflect the views, assumptions, expectations, and opinions of the Company as of the date of this Presentation, , and may include, without limitation, changes in general economic conditions as a result of COVID-19, all of which are accordingly subject to change. Any such estimates, assumptions, expectations, forecasts, views or opinions set forth in this Presentation constitute the Company's judgments and should be regarded as indicative, preliminary and for illustrative purposes only. The forward-looking statements and projections contained in this Presentation to be materially different from the expectations of future results, performance of financial condition. Although such forward-looking statements have been made in good faith and are based on assumptions we believe to be reasonable, there is no assurance that the expected results will be achieved. Many factors could adversely affect our business and financial performance. We discussed a number of material risks in our definitive proxy filed with the Securities and Exchange Commission on April 7, 2021 and other filings with the Securities and Exchange Commission. Moreover, we operate in a very competitive and rapidly changing environment. New risk factors, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We expressly disclaim any responsibility to update forward-looking statements on

This Presentation also includes outlook for fiscal 2021 that was announced on May 13, 2021. Our fiscal 2021 outlook has not been updated and does not take into consideration any developments since such date. Our achievement of the results included in or prior outlook is subject to risks and uncertainties, including those disclosed in our filings with the Securities and Exchange Commission. Our outlook does not take into account the impact of any unanticipated developments in our business or changes in our operating environment, nor does it take into account any unannounced acquisitions, dispositions or unannounced financings during 2021. Our 2021 outlook does include expected results from the anticipated acquisition of certain distributors in the first half of 2021. In addition, given the uncertainty in the environment we are operating in, we remain cautious of the potential risk for further market closures from new COVID-19 strains and the uneven global rollout of the vaccines. Our outlook assumes a largely reopened global market, which would be negatively impacted if closures persist or are re-implemented.

This presentation includes references to non-GAAP financial measures, including but not limited to Adjusted EBITDA. Such non-GAAP measures should be considered only as supplemental to, and not as superior to, financial measures prepared in accordance with GAAP.

This Presentation does not constitute an offer or invitation for the sale or purchase of the securities, assets or business described herein or a commitment of the Company with respect to any of the foregoing, and this Presentation shall not form the basis of any contract.

This Presentation contains information derived from third party sources, including research, surveys or studies conducted by third parties, information provided by customers and/or industry or general publications. While we believe that such third party information is reliable, we have not independently verified, and make no representation as to the accuracy of, such third party information. This Presentation contains financial forecasts. These projections are for illustrative purposes only and should not be relied upon as being necessarily indicative of future results. Inclusion of the prospective financial information in this presentation should not be regarded as a representation by any person that the results contained in the prospective financial information will be achieved.

# BEAUTYHEALTH MANAGEMENT PRESENTERS



CLINT CARNELL Chief Executive Officer Experience: 25 Years

#### CEO of HydraFacial since December 2016

- Founder of Orange Twist
- Head of Surgical for Bausch + Lomb
- Chief Operating Officer at Solta Medical
- Johnson & Johnson/Chiron





- Joined HydraFacial in September 2020
- Prior to joining HydraFacial, was the COO and CFO of The VOID, a virtual reality entertainment company
- Served as CFO for a number of companies such as SharkNinja, Gymboree, and bebe
- Deloitte M&A and Financial Advisory Services



LIYUAN WOO Chief Financial Officer

Experience: 23 Years

### WE ARE


# $\otimes$ **BEAUTYHEALTH**

Deeply Connecting You to the BeautyHealth Community Where You Live, Work & Play

CONSUMER	EDUCATOR	'AND' COMPANY
We take the consumer's view, providing them with experiences tailored to their needs	We provide education and support to our core customers, estheticians & providers, to ensure the quality of experiences for the community	We are an 'and' company, forging strategic partnerships throughout our ecosystem. The ecosystem we're building benefits everyone – the consumer, customer and our company

### MASSIVE GLOBAL OPPORTUNITY

### 2023 Beauty Health Estimated TAM (\$Billions)



### BEAUTY HEALTH CATEGORY CREATOR

### RESULTS SIMILAR TO A PROFESSIONAL MEDICAL TREATMENT WITH THE EXPERIENCE OF A CONSUMER BRAND



### SKIN CORRECTION

Medical delivery technology-focused Lasers, Ultrasound, Fillers, Toxins

### SKIN CARE

Daily, over-the-counter skin care Serums, Creams, Lotions, Supplements

### SKIN HEALTH

# hydrafacial

Highly effective, non-invasive and approachable treatment Bridging professional and retail skin care markets

### 3 STEPS. 30 MINUTES. THE BEST SKIN OF YOUR LIFE!



Uncover a new layer of skin with gentle exfoliation and relaxing resurfacing, using signature solutions.





**UPGRADES** 


BASE TIP



Remove debris from pores with painless suction. Nourish with intense moisturizers that quench skin.



**EXTRACTION TIP** 



Saturate the skin's surface with antioxidants and peptides to maximize your glow.



### VORTEX FUSION TIP





### Personalized Treatment Enhancements



BOOSTERS

Boosters address specific skin concerns such as acne, hyperpigmentation, dry skin and wrinkles



#### KERAVIVE

Keravive is a relaxing treatment designed to cleanse, exfoliate, nourish, and hydrate the scalp for healthier and fuller-looking hair


1.5 Boosters of which /

are partner boosters

#### GLOBAL SKINCARE & HAIRCARE SALES (\$B)







SPA SERVICES GROWING ACROSS ALL TYPES OF TREATMENTS, PARTICULARLY IN FACIALS

Source: Euromonitor 2020 and 2019. Note: Statistics for Global skincare & haircare reflect post-COVID conditions while all other data is from pre-COVID reports.



expected growth in U.S. medical spa services (2017–2025)



6.4%

expected growth in U.S. spa facilities (2017–2022)



14.0% expected growth in U.S. skin care specialists (2016–2026)


### CONSUMERS INCLINED TO SPEND ON BEAUTY & HEALTH

****	experiential	<ul> <li>Aging millennials are spending more on skincare, preferring experiences over products</li> <li>Holistic, in-side-out beauty</li> <li>Increased emphasis on rituals</li> </ul>
S	growth in disposable Income	<ul> <li>As U.S. economy grows, consumers have more disposable income to spend on premium products</li> </ul>
	CHANNEL GROWTH & DYNAMICS	<ul> <li>Multi-brand retailers (e.g., Sephora)</li> <li>Shift to digital</li> <li>Travel retail</li> <li>Consumers embracing affordable luxury</li> </ul>
R	INFLUENCERS & SOCIAL MEDIA DRIVING PURCHASE DECISIONS	<ul> <li>Online demos, which originally gained popularity in cosmetics, are becoming increasingly influential in skincare</li> <li>Skincare increasingly valued in age of selfies/social media</li> </ul>
	EMBRACING NATURAL & INCLUSIVITY	<ul> <li>Showcasing skin vs covering it up</li> <li>Clean, sustainable, "natural-ish"</li> <li>All-in beauty: gender, age, skin type</li> </ul>
	NEXT GEN BEAUTY	<ul><li>Personalization</li><li>Digital beauty</li></ul>

### FAVORABLE MARKET SHIFTS BENEFITING THE HYDRAFACIAL BUSINESS MODEL



## THE POWER OF THE NATION




Source: Third party research 2019; reflects pre-COVID conditions. Note: 2021E figures based on Net Sales guidance provided May 13, 2021, subject to all the qualifications and assumptions as of such date and does not reflect any developments, updates or changes since that date. Adjusted EBITDA is a nonGAAP financial measure. For a description of Adjusted EBITDA and a reconciliation to net loss, please see the Appendix. (1) Excludes Shipping / Other Revenue. Based on 2019A as % to sales. 2019 is more meaningful than 2020 given the pandemic disruption.

# THE MASTER PLAN

- 1. Sell a lot of products, use that money to ...
- 2. Invest in our skineare providers, use that relationship to ...
- 3. Find the consumers and build a direct relationship.
- 4. Leverage technology to connect them wherever, whenever & forever.
- 5. Build the ultimate flywheel of influence!

### HYDRAFACIAL NPS RANKS HIGHEST ACROSS BRANDED AESTHETICS AND MEDTECH PEERS



Source: Third party research July 2019; reflects pre-COVID conditions.

Note: NPS = Net Promoter Score as of 2019; Other brands listed are top 5 treatment and top 5 skincare brands used by HydraFacial users; N = Number of responses.

# TODAY

### TOMORROW



### Systems account for 49% of Sales<sup>1</sup>

- The patented HydraFacial systems generate~ 3.2M treatments performed annually
- One-time placement generates treatments (revenue) for 3-7 yrs


Consumables account for 51% of Sales<sup>1</sup>

• Every treatment uses



• Through which flow









### KERAVIVE SYSTEM

HOME EXTENSION

PERK AT RETAIL


• And customizable

### leading presence around the Globe

Loved in **87** Countries Worldwide


17,000+ Delivery Systems

> 14 Direct Markets 2021E



# LOVED AROUND THE WORLD

### POWERFUL FLYWHEEL DESIGNED TO DRIVE COMPETITIVE POSITIONING



#### Differentiated offering to build brand

- Technologically advanced offering with high consumer and provider engagement
- Customization/Personalization to skin concern

#### Strong base of engaged consumers to fuel growth

- 50–60% Millennials (vs. ~40% of facial users), a highly engaged demo
- 15% of users get 4+ HydraFacial treatments in a given year
- 40 NPS (vs. 5–15 NPS for other skincare brands used by our customers)

#### Passionate esthetician community to recommend HydraFacial

- Avid social discussion; 5x more Esthetician posts than competitors
- Estheticians actively recommending (80 NPS; 45% of users learned about HydraFacial from their provider)
- Estheticians make ~20% more than from a traditional facial

#### Favorable spa/clinic economics to increase HydraFacial share

• Payback of delivery system in ~5 months

#### Growing installed base to fund new investments

- As HydraFacial grows, investing in training to expand upon esthetician loyalty
  - Investing in targeted S&M investments to create deeply loved brand and R&D efforts to improve offering/create innovative products

### led by A Visionary and Experienced Management Team





CLINT CARNELL Chief Executive Officer

Experience: 25 Years



SOLTAMEDICAL\*

ORANGETWIST

GAMBRO.

**BAUSCH+LOMB** 



MINGO KU VP & GM, APAC

Experience: 22 Years



SOLTAMEDICAL\*





LIYUAN WOO Chief Financial Officer

Experience: 23 Years



**GYMBORee** 

bebe Shark NINJA

Deloitte.

KATE GILBERT

VP & GM, EMEA

Experience: 30 Years

SUNEVA

BOMARIN

SOLTAMEDICAL\*



JWALA KARNIK, M.D. EVP, Global Strategy & Partnerships

SUNEVA

iovera°

Experience: 29 Years

Chief Talent Officer Experience: 33 Years

DEB RODRIGUEZ



Johnson-Johnson

McKinsey &Company



MARK PRICE VP, RA, QA, R&D

Experience: 35 Years







ROSEMARIE HOLCOMB VP, Brand & Consumer Engagement

Experience: 12 Years



### StanleyBlack&Decker

IEFF KUCKENBAKER

Chief Information Officer

Experience: 20 Years

FLUIDRA

BOART LONGYEAR



DAN WATSON EVP, Sales U.S.


Experience: 36 Years



stryker



## GROWTH PROFILE



#### KEY TAKEAWAYS

- Significant historical revenue growth with 2020 negatively impacted by COVID-19
- Rebound experienced in first quarter 2021 despite continued COVID impact
- Historically strong adjusted EBITDA performance and an asset light structure that requires minimal CAPEX investment
- Expecting to invest in growth in 2021 & 2022 through higher expenses and CAPEX
  - \$15M 2021 CAPEX spend expected
- Expect continued strong profitable growth, as well as strong cash flows to support continued investments and M&A activities as we create shareholder value

# STRATEGIC INVESTMENTS



### CONSUMER ENGAGEMENT POWERHOUSE


~3 BILLION Media Impressions Anticipated 2021

> Significant ROI on Consumer Activations

> > 170%

~250,000 Provider Searches Anticipated for 2021

> 16% Instagram Engagement Rate



Source: Third party research 2019, reflecting PreCOVID conditions. Other data points based on best estimated consumer behavior and previous baseline of purchases

# PROVIDER & AESTHETICIAN EDUCATION

# hydrafacial CONNECT

Goal to be the world's largest educator and deployer of aesthetic professionals.






"This is everything I wish I would have learned in aesthetics school."






HFX: 2-day HydraFacial Experience



Podcasts Expert Hours Business Building Webinars Treatment Protocol Webinars

# INTERNATIONAL SCALING

We are investing in sales & marketing globally to grow consumer demand... AND we are scaling our infrastructure to support it



Pictured: London, Dubai, & Shanghai – 2021 pop ups & plans for permanent flagship storefronts

# INVESTMENT HIGHLIGHTS

1	CATEGORY CREATING PRODUCT	<ul> <li>Innovative product extension into IOT with data connection, personalization and clean beauty in skin and scalp health</li> </ul>
2	CUSTOMER LOYALTY	<ul> <li>High NPS scores in the industry</li> <li>Leading engagement rates on social media</li> <li>Favorable press coverage &amp; attendance at global pop-ups</li> </ul>
3	Commanding platform	<ul><li>Large install base continues to grow</li><li>Established partnerships across many channels</li></ul>
4	Multi-dimensional growth opportunities	<ul> <li>Digitally and categorically</li> <li>Organically through innovative R&amp;D and through M&amp;A</li> <li>Across skin (face and body) and scalp</li> </ul>
5	COMPELLING ECONOMIC PROFILE	<ul><li>High margin equipment and consumables</li><li>Vertically integrated supply chain</li></ul>
6	PROPRIETARY TECHNOLOGY	<ul> <li>Patented technology</li> <li>Successfully prosecuted challengers of trademarks, IP, and litigated across the globe</li> </ul>
7	EXPERIENCED MANAGEMENT AND BOARD	<ul><li>Deep aesthetic expertise in the CEO and Board</li><li>Experienced executive management team</li></ul>

### APPENDIX -SUPPLEMENTAL NON-GAAP FINANCIAL MEASURES ADJUSTED EBITDA

	Fiscal year ended December 31,									
Unaudited (in millions)	2020		2019		2018		2017		2016	
Net loss	\$	(29.2)	\$	(1.6)	\$	(0.3)	\$	8.0	\$	(14.0)
Adjusted to exclude the following:										
Depreciation and amortization expense		14.5		13.9		11.5		10.0		3.2
Interest expense		21.3		17.1		10.1		6.6		1.0
Income tax expense		(9.3)		(1.3)		0.3		(11.4)		(2.8)
Management fees (1)		1.5		1.8		3.2		1.2		14.2
Facility relocation costs (2)		-		4.0		-		-		-
COVID-19 related costs (3)		3.1		-		-		-		-
Transaction related costs (4)		4.2		1.7		0.4		-		13.4
One-time patent lawsuit cost (5)		-		1.4		-		-		-
Other non-recurring and one-time fees (6)		1.6		(0.3)		1.0		3.0		0.7
Adjusted EBITDA	\$	7.7	\$	36.7	\$	26.2	\$	17.4	\$	15.6
Adjusted EBITDA Margin		6.5 %		22.0 %		23.3 %		26.4 %		32.6 %

(1) Represents quarterly management fees paid to the majority shareholder of the Company based on a pre-determined formula (including a recapitalization fee of \$2.0 million incurred during 2018). Upon consummation of Business Combination, these fees will no longer be paid. Because these fees will not have an ongoing impact, they have been excluded from the calculation of Adjusted EBITDA.

(2) Such amounts represent costs associated with the 2019 relocation to a new assembly and warehouse facility that was completed during December 2019. These costs are nonrecurring and are directly attributable to the relocation that was finalized in December 2019 and include duplicate rental expense, and the write-off of certain capitalized costs associated with our previous facility.

(3) Such costs represent COVID-19 related restructuring costs including write-off of expired consumables, discontinued product lines, human capital and cash management consultant fees in relation to Covid restructuring.

(4) Such amounts represent direct costs incurred to prepare the Company to be marketed for sale by the Company's shareholders in previous periods.

(5) During 2019, the Company incurred approximately \$1.4 million to defend certain patents that were being infringed upon.

#### (6) Such costs primarily represent personnel costs associated with restructuring of HydraFacial's salesforce and costs associated with former warehouse and assembly facility during the transition period offset by a legal settlement received in favor of HydraFacial.

Source: Internal unaudited information for 2016 and 2017. 2018-2020 based on Definitive proxy statement filed on April 7, 2021 with the SEC. Adjusted EBITDA and Adjusted EBITDA Margin are key performance measures that Management uses to assess its operating performance. Because Adjusted EBITDA and Adjusted EBITDA and Adjusted EBITDA margin facilitates internal comparisons of the Company's historical operating performance on a more consistent basis, the Company uses these measures for business planning purposes. The Company also believes this information will be useful for investors to facilitate comparisons of its operating performance and better identify trends in its business.

The Company calculates Adjusted EBITDA as net income (loss) adjusted to exclude: other (income), net; interest expense; provision for income taxes; depreciation and amortization expense; stock-based compensation expense; and one-time or non-recurring items such as transaction costs, non-recurring legal fees associated with certain actions to defend its intellectual property, manufacturing and freight costs related to inefficiencies due to capacity constraints prior to moving into its new warehouse and assembly facility in December 2019, restructuring costs associated with COVID-19, Management Fees incurred from its private equity owners; and Foreign

### WE ARE

# 

DEMONSTRATING EXCITING GROVVTH... AND A PROFITABLE & SCALABLE BUSINESS MODEL... IN A MARKET WITH HUGE GLOBAL OPPORTUNITY.

WE ARE A CATEGORY CREATOR...